Patents Represented by Attorney, Agent or Law Firm Benjamin Aaron Adler
  • Patent number: 8053052
    Abstract: Provided herein are protective laminate devices comprising a biocompatible non-adherent substance and a fast-setting adhesive and methods of use. Also provided is a dispenser for an adhesive tape. The protective laminate devices and methods may be used for wound closure.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: November 8, 2011
    Inventors: Kevin S. Marchitto, Stephen T. Flock
  • Patent number: 8053199
    Abstract: The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: November 8, 2011
    Inventors: Allan R. Brasier, William J. Calhoun, Gary D. Boetticher
  • Patent number: 8052962
    Abstract: Provided herein is an oral soap composition comprising an orally-acceptable soap base effective to clean teeth that includes one or more natural oils, a saponifying agent and distilled water. The oral soap composition may be liquid or solid. Also provided are oral soap compositions comprising an essential oil for flavoring.
    Type: Grant
    Filed: February 22, 2007
    Date of Patent: November 8, 2011
    Inventor: Karen A. Adler
  • Patent number: 8030447
    Abstract: The present invention is directed to peptide sequences that were identified from combinatorial libraries and could serve as substrates of plague plasminogen activator (Pla). Another aspect of the present invention is drawn to peptides derived from the substrates for Pla as a result of chemical modifications leading to specific inactivation of the proteolytic activity of Pla. Additionally, the present invention is directed to the use of the substrates identified herein in the detection of bacteria expressing omptin family of proteases which includes Y. pestis. Furthermore, the present invention is also directed to the use of the inhibitors identified herein in the prevention and treatment of infection caused by these bacteria.
    Type: Grant
    Filed: September 20, 2007
    Date of Patent: October 4, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Vladimir L. Motin, Sadhana Chauhan, Scott R. Gilbertson, Anton Agarkov, Pedro Lory
  • Patent number: 8027039
    Abstract: Provided herein are methods for imaging subwavelength structures in three dimensions and with high resolution. The methods comprise illuminating subwavelength structures with an illuminating wavelength of light and detecting the self-image generated thereby at a distance distal to the structures. Also provided is a method for confining propagating light to a sub-diffraction limit dimension by illuminating a surface of a metal structure with subwavelength features with a wavelength of coherent light such that light propagating from the features is confined to a dimension that is a sub-diffraction limit thereof.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: September 27, 2011
    Assignee: University of Maryland, Baltimore
    Inventors: Joseph R. Lakowicz, Mustafa Habib Chowdhury, Chandran R. Sabanayagam
  • Patent number: 8014855
    Abstract: Provided herein is a device for altering a biological membrane in an individual comprising a means for delivering energy to the surface of the biological membrane, a means for monitoring a physiological state of the biological membrane during delivery of said energy, a means for modulating delivery of the energy to the biological membrane where the modulating is in response to a change in the monitored physiological state. Also provided is a device to control the permeation of substance across a biological membrane and methods for use of these devices.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: September 6, 2011
    Assignee: Rocky Mountain Biosystems, Inc.
    Inventors: Kevin S. Marchitto, Stephen T. Flock
  • Patent number: 8014494
    Abstract: Provided herein are methods and systems for designing a radiation treatment for a subject using single arc dose painting. The methods and systems comprise an algorithm or a computer-readable product having the same, to plan the radiation treatment. The algorithm converts pairs of multiple leaf collimation (MLC) leaves to sets of leaf aperture sequences that form a shortest path single arc thereof where the pairs of MLC leaves each aligned to an intensity profile of densely-spaced radiation beams, and connects each single arc of leaf apertures to form a final treatment single arc. Also provided is a method for irradiating a tumor in a subject using single arc dose painting.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: September 6, 2011
    Assignee: University of Maryland, Baltimore
    Inventors: Cedric X. Yu, Shuang Luan, Danny Z. Chen, Matthew A. Earl, Chao Wang
  • Patent number: 7999161
    Abstract: Provided herein are methods and system to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or therewithin. Pulsed electromagnetic radiation, e.g., optical radiation, having a wavelength spectrum selected for a peak wavelength near to or matching a peak absorption wavelength of the nanoparticulates selectively heats the nanoparticulates thereby generating vapor microbubbles around the clusters causing damage to the targets without affecting any surrounding medium or normal cells or tissues. Also provided is a method of treating leukemia using the methods and system described herein.
    Type: Grant
    Filed: January 22, 2006
    Date of Patent: August 16, 2011
    Inventors: Alexander Oraevsky, Dmitri Lapotko
  • Patent number: 7983850
    Abstract: Provided herein is a method for gene expression profiling multiple myeloma patients into distinct subgroups via DNA hybridization and hierarchical clustering analysis of the hybridization data where the results may further be used to identify therapeutic gene targets. Also provided is a method for controlling bone loss in an individual via pharmacological inhibitors of DKK1 protein. In addition provided herein is a method for diagnosing multiple myeloma using a 15-gene model that classifies myeloma into groups 1-7.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: July 19, 2011
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: John D. Shaughnessy, Bart Barlogie, Fenghuang Zhan
  • Patent number: 7967750
    Abstract: The present invention provides a device and methods of lie detection utilizing electrogastrography to monitor changes in the gastric electric rhythm of a subject. Also provided are methods of discriminating between the stress of deception induced in a subject during a lie detection examination and the stress of the examination itself.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: June 28, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jiande Chen, Pankaj J. Pasricha, Trisha Pasricha
  • Patent number: 7968698
    Abstract: The present invention provides core promoter motif ten elements (MTE) and core promoter constructs comprising the MTEs and an initiator element (Inr) in combination with one or both of a TATA box and a downstream promoter element (DPE) which increases gene expression over the strongest known core promoters. Particularly, an optimized or super core promoter is provided which comprises Inr, MTE, TATA box and DPE elements. The present invention also provides expression vectors and host cells comprising the core promoter constructs. Additionally, methods of increasing production of a protein using the core promoter constructs are provided.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: June 28, 2011
    Assignee: The Regents of the University of California
    Inventors: James T. Kadonaga, Tamar Gershon
  • Patent number: 7967839
    Abstract: Provided herein are methods, devices and compositions to conductively or to inductively fix substrates, including tissues, using electromagnetic energy. Also provided is a method of controlling the fixing process via feedback monitoring of a property of the composition and/or of the electromagnetic energy used.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: June 28, 2011
    Assignee: Rocky Mountain Biosystems, Inc.
    Inventors: Stephen T. Flock, Kevin S. Marchitto
  • Patent number: 7939321
    Abstract: The present invention provides DNA encoding a TADG-15 protein as well as a TADG-15 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. The present invention further provides for methods of inhibiting TADG-15 expression and/or protease activity, methods of detecting TADG-15 mRNA and/or protein and methods of screening for TADG-15 inhibitors. Additionally, the present invention provides for cell-specific targeting via TADG-15 and methods of vaccinating an individual against TADG-15. The methods described are useful in the diagnosis, treatment and prevention of cancer, particularly breast and ovarian cancer.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: May 10, 2011
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Timothy J. O'Brien, Hirotoshi Tanimoto
  • Patent number: 7935531
    Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. Specifically, the present invention relates to expression of hepsin protease. The detected proteases are themselves specifically over-expressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: May 3, 2011
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin
  • Patent number: 7935679
    Abstract: Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifing genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: May 3, 2011
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: John D. Shaughnessy, Bart Barlogie, Fenghuang Zhan
  • Patent number: 7927795
    Abstract: Gene expression profiling and hierarchal clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1/Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1/Ep-CAM by monoclonal chimeric/humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: April 19, 2011
    Assignee: Board of Trustees of the University of Arkansas
    Inventor: Alessandro D. Santin
  • Patent number: 7923010
    Abstract: Disclosed are methods for treating an autoimmune disease or condition in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Also disclosed are methods for suppressing hyperacute graft rejection in a subject. The methods include administering to the subject a compound which inhibits the subject's classical complement pathway. Compositions which include a specific inhibitor of C1q and a pharmaceutically acceptable excipient are also described.
    Type: Grant
    Filed: September 11, 2004
    Date of Patent: April 12, 2011
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Premkumar Christadoss, Erdem Tuzun
  • Patent number: 7912538
    Abstract: Provided herein is a device for controlling the release of a substance at a site of interest in a biological membrane comprising a means of monitoring a physiological state at the site of interest; and a means of releasing a variable amount of the substance to the site of interest where the amount varies in response to the status of the monitored physiological state. Also provided are methods of using the device.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: March 22, 2011
    Assignee: Rocky Mountain Biosystems, Inc
    Inventors: Kevin S. Marchitto, Stephen T Flock
  • Patent number: 7902145
    Abstract: Methods of sterilizing dermal fillers and injectable collagen material have been developed which reduce the level of active biological contaminants or pathogens without adversely affecting the material, i.e., wherein the dermal fillers and injectable collagen material retain their same properties before and after its terminal sterilization. In one embodiment the method for sterilizing the dermal filler or injectable collagen material that is sensitive to radiation contains the steps of protecting the filler or material from radiation, and irradiating the filler or material with a suitable dose of radiation for a time and at a rate effective to sterilize the filler or injectable material. In a preferred embodiment the method for sterilizing the dermal filler or injectable collagen material that is sensitive to radiation includes the steps of a) freezing the filler or material at a temperature below its freezing temperature, which is generally below 0° C.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: March 8, 2011
    Assignee: Albiorex, LLC
    Inventors: George Chu, C. Randall Harrell, Hector J. Gomez
  • Patent number: RE42782
    Abstract: An instrument for measuring aberration refraction of an eye is provided, having: a lens system defining an instrument optical axis and an alignment device for aligning the visual axis of the eye with the instrument optical axis. A light source produces a probing beam that is projected through the lens system parallel to the instrument optical axis and is selectably positionable partially off-set from the instrument optical axis for entering the eye parallel to the instrument optical axis at a plurality of locations on the cornea of the eye. A first photodetector measures the position of a first portion of the probing beam light scattered back from the retina of the eye to measure aberration refraction of the eye at a plurality of locations. A second photodetector synchronously measures the position of a second portion of the probing beam light reflected back from the cornea of the eye.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: October 4, 2011
    Assignee: Tracey Technologies, LLC
    Inventors: Vasyl Molebny, Ioannis Pallikaris, Youssef Wakil, Sergiy Molebny